While not all the data from its trial involving 40,000 participants in Latin America and Europe have been assessed yet, the company said interim results show the vaccine has an efficacy of 47% against COVID-19 disease of any severity.
from Section Page News - Modern Healthcare https://ift.tt/35tEyLQ
No comments:
Post a Comment